Open-label pilot study of lisdexamfetamine for cocaine use disorder.
Am J Drug Alcohol Abuse
; 47(3): 402-409, 2021 05 04.
Article
en En
| MEDLINE
| ID: mdl-33797985
ABSTRACT
Background:
Cocaine use disorder (CUD) is a substantial public health problem with no FDA-approved medication treatments. Psychostimulants have shown promise as pharmacotherapy for CUD. Lisdexamfetamine, a novel prodrug psychostimulant, is roughly 40-50% as potent as dextroamphetamine.Objectives:
To evaluate the safety, tolerability, and optimal dosing of lisdexamfetamine for treating CUD.Methods:
Open-label, 8-week trial of 17 CUD adults. Participants were titrated to the maximum tolerated dose of 140 mg over 2-week period and maintained for 4 weeks, followed by a two-week taper period. The primary outcome measures were the maximum daily dose achieved during the study period and tolerability as measured by medication-related study drop-out.Results:
Among the 16 participants with post-enrollment data, the mean dose of lisdexamfetamine achieved was 118.1 mg (standard deviation (SD) = 40.4), mean retention was 6.5 weeks (SD = 2.0), and no participants discontinued study medication due to adverse effects. Four participants had dose reductions due to adverse effects and continued in the trial. Six participants (37.5%) were abstinent for the last 3 weeks of their study participation. Mean dollars of cocaine spent per day significantly decreased from $19.72 at baseline to $7.57 during the last 3 weeks of study participation (t15 = 3.60, p = .003). The mean percent of using days significantly decreased from 25% at baseline to 12% during the last 3 weeks of study participation (t15 = 3.33, p = .005).Conclusion:
The use of lisdexamfetamine for CUD in doses ranging to 140 mg daily was safe and generally well tolerated.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Trastornos Relacionados con Cocaína
/
Dimesilato de Lisdexanfetamina
/
Estimulantes del Sistema Nervioso Central
Límite:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Am J Drug Alcohol Abuse
Año:
2021
Tipo del documento:
Article
País de afiliación:
Estados Unidos